Sirolimus

Analyzing The Side Effects Of Sirolimus Stents

Based on findings of a recent study researchers from Sweden say they have found that implantation //of a sirolimus-eluting stent is associated with coronary vasoconstriction in areas adjacent to the treated vessel that is not seen with bare metal stents. Sirolimus-eluting stents are widely us...

Newest Coated Stent Does Well in Real-World Trial

...49 people given Xience stents with individuals who previously had stents implanted -- 450 with bare-metal stents, 508 with stents coated with the drug sirolimus and 576 with stents coated with the drug paclitaxel. The data include people with multiple artery blockages and some treated after heart attacks. I...

New Type of Stent Appears Safe, Effective

...ity Hospital reported that biolimus-eluting stents were as effective as the sirolimus stent in terms of the number of patients who experienced a combination of c... -- 9 percent for the biolimus group and 11 percent for those receiving the sirolimus stent. There were also no significant difference between the biolimus ...

Immune Response May Hinder Stem Cell Treatments

...se an immune response." Medicating the mice with normal immune systems with a combination of two common anti-rejection compounds -- tacrolimus and sirolimus -- allowed those cells to survive for up to 28 days, the team said. More information The U.S. National Institutes of Health has more about s...

Drug may prolong organ life in noncompliant kidney transplant patients

... of Nephrology, shows that the anti-rejection drug sirolimus (brand name Rapamune) may help prolong the clinica...etect in its early stages. Long acting drugs like sirolimus may help with this problem." A team of five UC...g in the blood stream, the assay demonstrated that sirolimus caused a significantly lower level of mitogenic re...

Anti-Rejection Drug May Boost Diabetes in Kidney Transplant Patients

... Those treated with sirolimus faced up to 66% increased risk of disease after op...ay News) -- Treatment with the anti-rejection drug sirolimus may lead to increased risk of diabetes in kidney t...ransplant. Compared to other anti-rejection drugs, sirolimus was associated with a 36 percent to 66 percent inc...

Anti-rejection drug may increase risk of diabetes after kidney transplant

...plantation, treatment with the anti-rejection drug sirolimus may lead to an increased risk of diabetes, reports.... "We demonstrated a robust association between sirolimus and diabetes after transplantation in a large grou...es before their kidney transplant. Treatment with sirolimus was analyzed as a possible contributor to the risk...

New Drug-Coated Stent Does Well in Early Trial

...proved, the Xience stent would be the fourth drug-coated stent on the American market. It would compete with the Cypher, which is coated with the drug sirolimus and marketed by Johnson and Johnson; Taxus, a Boston Scientific product coated with paclitaxel; and the newest entry, Medtronic's Endeavor, coated wit...

Anticoagulant Drugs Had Similar Outcomes After Angioplasty

...n 90 minutes after the procedure, says an Italian study. The researchers also found that patients who received coated stents that released the drug sirolimus had a lower risk of major adverse cardiac events within eight months than patients who received uncoated stents. The study was to be presented Sund...

Comparison of anticoagulants for angioplasty show similar outcomes

...ofiban had similar outcomes for some cardiac measures within 90 minutes after the procedure, while patients who received stents that released the drug sirolimus had a lower risk of major adverse cardiac events within 8 months than patients who received uncoated stents, according to a JAMA study being released ...

Sirolimus in Medical Technology

MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration

Sirolimus Demonstrates Favorable Safety Profile and Improvements in Visual Acuity UNION CITY, Calif., Feb. 25 /PRNewswire/ -- MacuSight(TM), Inc., a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced p...

MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema

Sirolimus Demonstrates Favorable Safety Profile and Improvements in Visual Acuity UNION CITY, Calif., Oct. 1 /PRNewswire/ -- MacuSight(TM), Inc., a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced po...

Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents

...was highlighted in separate presentations, one focusing on pre-clinical results of an endothelial cell capture (EPC) surface on an abluminal, low dose sirolimus eluting stent (pro-healing SES), the other focusing on the company's bioabsorbable stent developments. Greg Kaluza, M.D., Ph.D., Director of Oper...

Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents

...rials that aimed to assess the differences between sirolimus and Paclitaxel (having different polymers and diff...mulations of stents with Paclitaxel (Infinnium) or sirolimus (Supralimus), eluted in biodegradable polymers, ar...t is that most previous comparative trials between sirolimus & Paclitaxel used stents with two different platfo...

Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease

...can be found at http://www.cordis.com . *Cordis Corporation has entered into an exclusive worldwide license with Wyeth for the localized delivery of sirolimus in certain fields of use, including delivery via vascular stenting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceut...

Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent

...can be found at http://www.cordis.com . *Cordis Corporation has entered into an exclusive worldwide license with Wyeth for the localized delivery of sirolimus in certain fields of use, including delivery via vascular stenting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceut...

Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent

...can be found at http://www.cordis.com . *Cordis Corporation has entered into an exclusive worldwide license with Wyeth for the localized delivery of sirolimus in certain fields of use, including delivery via vascular stenting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceut...

Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety

...ation or future events or developments.) *Cordis Corporation has entered into an exclusive worldwide license with Wyeth for the localized delivery of sirolimus in certain fields of use, including delivery via vascular stenting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceut...

Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline

...n(TM). US filing is in process. Finally for this section this quarter, Torisel(TM) is the brand name of temsirolimus, an analog of the mTOR inhibitor sirolimus (rapamycin) developed by Wyeth Research for the oral treatment of advanced renal cell carcinoma (RRC). Having received FDA approval in May 2007, the d...

Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in 'Real World' Uses

...ordis.com/">www.cordis.com . *Cordis Corporation has entered into an exclusive worldwide license with Wyeth for the localized delivery of sirolimus in certain fields of use, including delivery via vascular stenting. Sirolimus, the active drug released for the stent, is marketed by Wyet...

Sirolimus in Medical Products

Cypher Sirolimus-eluting Coronary Stent

Description:...sists of a proven antiproliferative drug, called "sirolimus", a controlled-release polymer, and a closed-cell stent delivery platform. Upon placement, sirolimus elutes into the vessel wall and impedes the process of neointimal hyperplasia, thereby significantly reducing the incidence of in-stent restenosis....
Company:Cordis Corporation

Cypher Stent

Description:...sists of a proven antiproliferative drug, called "sirolimus", a controlled-release polymer, and a closed-cell stent delivery platform. Upon placement, sirolimus elutes into the vessel wall and impedes the process of neointimal hyperplasia, thereby significantly reducing the incidence of in-stent restenosis....
Company:Cordis Corporation

Sirolimus in Biological News

REGiMMUNE presents enhanced efficacy data in preclinical transplantation models

...luate the efficacy of RGI-2001 in combination with sirolimus in transplantation tolerance induction in mouse mo...uded that the addition of a subtherapeutic dose of sirolimus enhanced the efficacy of RGI-2001 in both models. ...rvival of grafts in the skin transplant model over sirolimus single treatment. Likewise, GvHD mortality was re...

Genetic breakthrough offers promise in tackling kidney tumors

...ally controlled by the TSC1 and TSC2 genes. If the genes fail, mTOR is too active leading to tuberous sclerosis. The UK study tested the effects of sirolimus on kidney tumours in patients with tuberous sclerosis and a related condition, LAM, a lung and kidney disease affecting young women. The study is at t...

UAB wins $5.7M neurofibromatosis grant

...gator. Lee said three clinical trials will be the focus of the consortiums first studies. These include: A study of the immunosuppressant drug sirolimus (rapamycin) to treat plexiform neurofibromas, a condition where nerves become thick and misshapen due to abnormal cell and tissue growth. A stud...

Genetic 'roadmap' charts links between drugs and human disease

...cal School and Children's Hospital Boston and an investigator at the Dana-Farber Cancer Institute, identified the FDA-approved immunosuppressant drug, sirolimus (also known as "rapamycin"), as a therapeutic candidate for overcoming drug resistance in a form of human leukemia. These findings, as well as those f...

Diabetes researchers pioneer islet cell xenotransplantation in primate studies

...ejection. To combat that, the researchers administered an anti-IL-2 receptor and anti-CD154 (H106) antibody, while maintaining immunosuppression using sirolimus and belatacept (a second-generation high affinity derivative of CTLA4-Ig)9-11 on diabetic rhesus macaques transplanted with neonatal porcine islets. ...

Sirolimus in Biological Technology

Santen and MacuSight Announce Collaboration and License Agreement for Sirolimus in Ocular Diseases and Conditions

OSAKA, Japan and UNION CITY, Calif., June 2 /PRNewswire/ -- Santen Pharmaceutical Co., Ltd. and MacuSight, Inc. today announced that the two companies have entered into a research and development collaboration and license agreement for the Japanese and Asian development and commercialization o...

Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients

...roids in combination with low-dose CyA, Prograf or sirolimus (Siro). The primary endpoint of the study was rena...standard-dose CyA (29.0%), low-dose CyA (26.6%) or sirolimus (38.1%) groups. Graft loss excluding death was al...group (5.0%), the standard-dose CyA (7.2%) and the sirolimus group (7.5%). "After more than 20 years of co...

OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Impressive Results in Higher Risk Patients

...eluting stent (SES) featuring a combination of endothelial progenitor cell (EPC) capture technology and the abluminal deposition of a fully-absorbable sirolimus eluting matrix. "Each of these complex technologies on their own offer solutions to the interventionalist," said Seung-Jung Park, MD, PhD, chairp...

A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA)

...es describes an LC/MS/MS method for the simultaneous determination of four immunosuppressant drugs: Cyclosporin A (CsA), Tacrolimus (TAC, aka FK-506), sirolimus (SIR, aka Rapamycin) and Everolimus (EVE, aka RAD-001) (1, 2). The method is based on a simple and robust hardware configuration and shows to be fast ...